Results 1 to 10 of about 78,666 (255)
Arginase: shedding light on the mechanisms and opportunities in cardiovascular diseases
Cell Death Discovery, 2022 Arginase, a binuclear manganese metalloenzyme in the urea, catalyzes the hydrolysis of L-arginine to urea and L-ornithine. Both isoforms, arginase 1 and arginase 2 perform significant roles in the regulation of cellular functions in cardiovascular system,
Zhuozhuo Li +8 more
doaj +2 more sources
Frontiers in Immunology, 2021 Myeloid cell arginase-mediated arginine depletion with consecutive inhibition of T cell functions is a key component of tumor immune escape. Both, granulocytic myeloid-derived suppressor cells (G-MDSC) and conventional mature human polymorphonuclear ...
Verena Vonwirth +17 more
doaj +2 more sources
Frontiers in Pharmacology, 2020 Type 2 diabetes mellitus (T2DM) is becoming a major contributor to cardiovascular disease. One of the early signs of T2DM associated cardiovascular events is the development of vascular dysfunction.
Alia Shatanawi +5 more
doaj +2 more sources
Strategies to rescue the consequences of inducible arginase-1 deficiency in mice. [PDF]
PLoS ONE, 2015 Arginase-1 catalyzes the conversion of arginine to ornithine and urea, which is the final step of the urea cycle used to remove excess ammonia from the body.
Laurel L Ballantyne +9 more
doaj +7 more sources
Frontiers in Immunology, 2021 COVID-19 ranges from asymptomatic in 35% of cases to severe in 20% of patients. Differences in the type and degree of inflammation appear to determine the severity of the disease.
Matthew J. Dean +32 more
doaj +2 more sources
Arginase activities and global arginine bioavailability in wild-type and ApoE-deficient mice: responses to high fat and high cholesterol diets. [PDF]
PLoS ONE, 2010 Increased catabolism of arginine by arginase is increasingly viewed as an important pathophysiological factor in cardiovascular disease, including atherosclerosis induced by high cholesterol diets.
Aaron Erdely +7 more
doaj +7 more sources
Journal for ImmunoTherapy of Cancer, 2019 Background Tumor orchestrated metabolic changes in the microenvironment limit generation of anti-tumor immune responses. Availability of arginine, a semi-essential amino acid, is critical for lymphocyte proliferation and function.
Juan J. Miret +15 more
doaj +2 more sources
Restoring Ureagenesis in Hepatocytes by CRISPR/Cas9-mediated Genomic Addition to Arginase-deficient Induced Pluripotent Stem Cells [PDF]
Molecular Therapy: Nucleic Acids, 2016 Urea cycle disorders are incurable enzymopathies that affect nitrogen metabolism and typically lead to hyperammonemia. Arginase deficiency results from a mutation in Arg1, the enzyme regulating the final step of ureagenesis and typically results in ...
Patrick C Lee +14 more
doaj +5 more sources
Arginase: An emerging and promising therapeutic target for cancer treatment.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022 Arginase is a key hydrolase in the urea cycle that hydrolyses L-arginine to urea and L-ornithine. Increasing number of studies in recent years demonstrate that two mammalian arginase isoforms, arginase 1 (ARG1) and arginase 2 (ARG2), were aberrantly ...
F. Niu +9 more
semanticscholar +1 more source
Inducible arginase 1 deficiency in mice leads to hyperargininemia and altered amino acid metabolism [PDF]
, 2013 Arginase deficiency is a rare autosomal recessive disorder resulting from a loss of the liver arginase isoform, arginase 1 (ARG1), which is the final step in the urea cycle for detoxifying ammonia. ARG1 deficiency leads to hyperargininemia, characterized
Ballantyne, Laurel L. +6 more
core +14 more sources